On January 1, 2026, the maximum fair prices Medicare negotiated for ten of its costliest drugs will take effect, and the policy that pharmaceutical executives spent two decades calling impossible will become routine. The savings, projected by the Congressional Budget Office at roughly $6 billion in the first year, are large enough to be politically useful and small enough to discomfit nobody at Treasury. The strategic consequences, however, are not contained by that figure.
The Inflation Reduction Act, signed in August 2022, ended a four-decade prohibition on Medicare price negotiation that had been written into the Part D statute in 2003. The first ten drugs—selected by CMS in August 2023 and including Eliquis, Jardiance, Xarelto, Januvia, Farxiga, Entresto, Enbrel, Imbruvica, Stelara, and the insulin Fiasp/NovoLog—account for around 20 percent of total Part D gross spending. The negotiated prices announced by HHS in August 2024 ranged from 38 to 79 percent below the 2023 list price. Both numbers will be cited for years. Both are misleading in different directions.
What the negotiated prices accomplish on paper is the recovery of a portion of the gap between list and net—a gap that pharmacy benefit managers and pharmaceutical manufacturers have long monetized to the bewilderment of nearly everyone who has tried to understand it. The cuts compared to 2023 list price look dramatic; the cuts compared to confidential rebated net prices, which never appear in any public document, are considerably smaller. Several of the negotiated drugs were facing imminent generic or biosimilar competition anyway. In effect, the federal government locked in some discounts it would have received via the market, and a handful it would not.
The more consequential changes are upstream. Drugs become eligible for negotiation seven years after FDA approval if they are small molecules and eleven years if they are biologics. This four-year asymmetry, the so-called pill penalty, is now a structural input into every late-stage development decision in the industry. A small-molecule oncology drug that requires three or four years of clinical development plus the standard regulatory review timeline arrives in the market with perhaps three to four years of unconstrained pricing before negotiation eligibility begins, and roughly seven years before the negotiated price applies. A biologic of equivalent merit gets eleven and seven, respectively. Investment committees are not subtle, and they have noticed.
What this means in practice is that any small molecule whose commercial life depends on a multi-indication pipeline—where the first indication is a beachhead and subsequent ones add years of revenue—now lives under a regulatory clock that runs on the original approval date. The University of Chicago’s Tomas Philipson and others have argued that the pill penalty will redirect investment from small molecules to biologics in marginal cases, and the data emerging from late-stage portfolios in 2024 and 2025 suggests this is not theoretical. Several manufacturers have publicly acknowledged delays or terminations of small-molecule programs that would have served indications best treated by oral therapy.
The counterargument, advanced by the Biden administration’s economists and by groups like the Initiative for Medicines, Access, and Knowledge, is that any redirection from small molecules to biologics is a feature rather than a bug—biologics are harder to copy, less prone to manufacturing arbitrage, and often more clinically valuable. There is a version of this defense that holds together. There is another, less convincing version, which assumes that the molecules pharmaceutical companies pick are interchangeable with the molecules patients need, and which conveniently elides the long history of oral therapy as the dominant mode of chronic disease management. A patient with hypertension does not, on the whole, prefer an injection.
What the negotiation framework also does, less remarked, is encode a particular theory of innovation into Medicare’s pricing structure. The CMS methodology incorporates an analysis of clinical benefit relative to comparators, manufacturing costs, federal financial support for the drug’s development, and the unmet medical need addressed. These criteria sound reasonable in the abstract and become contentious in the particular. The negotiated price for Imbruvica, an ibrutinib-based therapy for several blood cancers, fell on the order of 38 percent. Manufacturers AbbVie and Johnson & Johnson have argued that the cut understates the drug’s value across multiple indications. CMS, citing comparator therapies, disagreed. There is no neutral arbiter in this dispute, only a bureaucracy with the final word.
A second-order effect that has received less attention than it deserves is what the negotiated price does to the rebate architecture downstream. Part D plan sponsors, working through their PBMs, have built their formularies around list-price-to-rebate spreads that have grown ornate and self-reinforcing. A negotiated maximum fair price compresses that spread, sometimes nearly to zero. This is mechanically helpful for patients whose cost-sharing is calculated on list price. It is structurally disruptive for plans whose direct and indirect remuneration depends on rebate flow. The plans will adjust. The adjustment will not be costless, and it will not, in the first instance, benefit the patient most. In a market this opaque, savings tend to drift toward whoever has the best information.
The second round of negotiation, announced in January 2025, expanded to fifteen drugs, including Ozempic and Wegovy under their semaglutide umbrella. Whether the inclusion of GLP-1 agonists in negotiation will accelerate or retard their use in cardiovascular and obesity indications is a question now being modeled at every major sell-side desk in pharma equities. The KFF analysis of round two noted that two of the drugs selected, including Ozempic, are still relatively early in their commercial lifecycle, suggesting that the negotiation regime will not, as some had hoped, simply target end-of-life-cycle assets. The strategic implication is that the negotiation calendar must now be priced into the launch curve of newly approved drugs in real time, not at some comfortable later date.
Beyond the pricing question lies a quieter institutional question. The negotiation process has created a durable bureaucratic capacity inside CMS for drug-level price-setting—an apparatus with statutory authority, internal expertise, and political constituencies. Such apparatuses do not contract. Whether or not future Congresses expand the negotiation regime to commercial markets, to a larger set of drugs, or to a shorter eligibility window, the institutional infrastructure to do so now exists. Industry strategists have understood this for some time, which is one reason the legal challenges to the IRA have continued past the policy’s implementation. The challenges are unlikely to undo the framework, but they buy time, and time has rarely been more valuable in this industry than it is now.
What the negotiated prices ultimately do, then, is much less than their critics feared and considerably more than their defenders are willing to claim. They will not bankrupt the pharmaceutical industry, which will continue to invest in the drugs whose risk-adjusted returns remain attractive under the new regime. They will not, in any direct sense, save patients much money at the pharmacy counter, since most Part D beneficiaries reach the catastrophic threshold quickly under the IRA’s separate $2,000 out-of-pocket cap. What they will do is restructure how drugs are chosen for development, which dosage forms are favored at the margin, which indications are pursued first, and how late-stage clinical trials are sequenced. None of this is visible in the $6 billion figure. None of it will be priced into the political debate. It will, however, show up in the medicines available a decade from now, and in their absence.
